Lainate – 26 March 2018 – Cassiopea SpA (SIX: SKIN), a clinical stage specialty pharmaceutical company focused on developing innovative and differentiated medical dermatology products, today announced the lists of candidates proposed for the board of directors at the annual general meeting of 5 April 2018, in Lainate, Milan (Italy).
The list proposed by Cassiopea’s shareholder Cosmo Pharmaceuticals NV consists of the following candidates: Jan de Vries (incumbent, non-executive, independent), Pierpaolo Guzzo (incumbent, non-executive, independent), Oyvind Bjordal (incumbent, non-executive, independent), and Diana Harbort (incumbent, executive). Their CV’s are available here on the Company’s website.
The list proposed by Cassiopea’s shareholder Heinrich Herz AG/Logisticable SA Group consists of the following candidate: Maurizio Baldassarini (new, non-executive, independent). His CV is available here on the Company’s website.
Cassiopea SpA is a clinical-stage specialty pharmaceutical company focused on developing and commercializing innovative and differentiated medical dermatology products. Our focus is on the topical treatment of acne, androgenic alopecia (or AGA) and genital warts. The portfolio comprises four unencumbered clinical candidates, for which Cassiopea owns the worldwide rights. The company plans to commercialize the products directly in the US and partner the products outside of the US. For further information on Cassiopea, please visit www.cassiopea.com.
Annual General Shareholders Meeting in Lainate, April 5, 2018
2018 Half Year Report, July 2018
Dr. Chris Tanner, CFO and Head of Investor Relations
Tel: +39 02 868 91 124
Some of the information contained in this press release may contain forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Cassiopea has no obligation to publicly update or revise any forward-looking statements.